Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getein BiotechSHSE:603387 -0.11%79 Return-on-Tangible-Asset is 12.26% as of Jun. 2026, which is 17% below its 10-year median of 14.78. GuruFocus rates SHSE:603387 with a GF Score™ of 79/100 and a GF Value™ of ¥8.02 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Getein Biotech ranks better than 75.47% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Getein Biotech's annualizedNet Income for the quarter that ended in Jun. 2026 was ¥432 Mil. Getein Biotech's average total tangible assets for the quarter that ended in Jun. 2026 was ¥3,524 Mil. Therefore, Getein Biotech's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 12.26%.
The historical rank and industry rank for Getein Biotech's Return-on-Tangible-Asset or its related term are showing as below:
SHSE:603387'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 6.25 Med: 14.78 Max: 38.63
Current: 8.27
During the past 13 years, Getein Biotech's highest Return-on-Tangible-Asset was 38.63%. The lowest was 6.25%. And the median was 14.78%.
SHSE:603387's Return-on-Tangible-Asset is ranked better than 75.47% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.92
vs SHSE:603387: 8.27
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Getein Biotech Return-on-Tangible-Asset Related Terms
Getein Biotech Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Getein Biotech's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603387 vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Getein Biotech's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getein Biotech Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Getein Biotech's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 12.26% mean?
Getein Biotech (SHSE:603387) has a Return-on-Tangible-Asset of 12.26% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Getein Biotech and its competitors. This is 17% below median its historical median of 14.78. Over the past decade, Getein Biotech's Return-on-Tangible-Asset has ranged from 6.25 to 38.63. According to the industry distribution chart, Getein Biotech ranks #209 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 24.5%.
Is Getein Biotech's Return-on-Tangible-Asset too high?
Getein Biotech's current Return-on-Tangible-Asset of 12.26% is 17% below median its 10-year median of 14.78. Over the past 10 years, this metric has ranged from a low of 6.25 to a high of 38.63. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.92. Getein Biotech's value of 12.26% is 1232.6% above this industry median. Based on the distribution chart, Getein Biotech ranks #209 out of 852 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Getein Biotech has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getein Biotech's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getein Biotech ranks #209 out of 852 companies for Return-on-Tangible-Asset. This places Getein Biotech in the top 25% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.92. Getein Biotech's value of 12.26% is 1232.6% above this benchmark. Historically, Getein Biotech's own Return-on-Tangible-Asset has ranged from 6.25 to 38.63 over the past decade. While the company's 10-year median is 14.78 vs. the industry median of 0.92, Getein Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.92, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Getein Biotech's current Return-on-Tangible-Asset of 12.26% is 1232.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Getein Biotech and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getein Biotech's current Return-on-Tangible-Asset is 12.26%, which is 17% below median its own 10-year median of 14.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Getein Biotech (SHSE:603387) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥8.02, compared to a current price of ¥9.32 — trading 16.2% above its estimated fair value. The current Return-on-Tangible-Asset is 12.26%, which is 17% below median its 10-year median of 14.78 and 1232.6% above the Medical Devices & Instruments industry median of 0.92. Getein Biotech's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Getein Biotech (SHSE:603387), the current Return-on-Tangible-Asset is 12.26% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getein Biotech (SHSE:603387) Overvalued in 2026?
Based on GuruFocus' analysis, Getein Biotech stock appears to be overvalued.
The current stock price of ¥9.32 is trading 16.2% above its estimated GF Value™ of ¥8.02.
GuruFocus considers Getein Biotech to be Modestly Overvalued.
Key valuation signals for SHSE:603387:
Return-on-Tangible-Asset: 12.26% (17% below median its 10-year median of 14.78)
GF Value™: ¥8.02 vs. price of ¥9.32 (16.2% above fair value)
Industry Position: 1232.6% above the Medical Devices & Instruments median (#209 of 852)
No single metric tells the full story. See the SHSE:603387 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
79GF Score
Get the complete analysis for SHSE:603387
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603387 has been successfully added to your 
